Rhumbline Advisers Anavex Life Sciences Corp. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Rhumbline Advisers holds 123,699 shares of AVXL stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,699

Previous 120,201 2.91%

Holding current value

$1.15 Million

Previous $682,000 94.72%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$5.11 - $12.56 $17,874 - $43,934	3,498 Added 2.91%	123,699 $1.33 Million
Q3 2024 Nov 12, 2024	BUY	$4.11 - $7.04 $3,748 - $6,420	912 Added 0.76%	120,201 $682,000
Q2 2024 Aug 01, 2024	BUY	$3.39 - $5.02 $55,233 - $81,790	16,293 Added 15.82%	119,289 $503,000
Q1 2024 May 09, 2024	BUY	$4.55 - $6.75 $11,702 - $17,361	2,572 Added 2.56%	102,996 $524,000
Q4 2023 Feb 08, 2024	BUY	$5.04 - $9.95 $6,733 - $13,293	1,336 Added 1.35%	100,424 $934,000
Q3 2023 Nov 09, 2023	SELL	$6.55 - $9.37 $19,977 - $28,578	-3,050 Reduced 2.99%	99,088 $649,000
Q2 2023 Aug 08, 2023	BUY	$7.66 - $9.5 $96,661 - $119,880	12,619 Added 14.1%	102,138 $830,000
Q1 2023 May 11, 2023	BUY	$8.32 - $11.75 $26,848 - $37,917	3,227 Added 3.74%	89,519 $767,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $17,748 - $33,477	2,320 Added 2.76%	86,292 $799,000
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $62,602 - $90,457	7,034 Added 9.14%	83,972 $867,000
Q2 2022 Aug 11, 2022	BUY	$7.31 - $12.84 $65,212 - $114,545	8,921 Added 13.12%	76,938 $770,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $67,264 - $122,167	6,906 Added 11.3%	68,017 $837,000
Q4 2021 Feb 10, 2022	BUY	$16.88 - $23.31 $12,778 - $17,645	757 Added 1.25%	61,111 $1.06 Million
Q3 2021 Nov 12, 2021	BUY	$16.82 - $25.75 $37,979 - $58,143	2,258 Added 3.89%	60,354 $1.08 Million
Q2 2021 Aug 05, 2021	BUY	$10.16 - $28.86 $76,230 - $216,536	7,503 Added 14.83%	58,096 $1.33 Million
Q1 2021 May 06, 2021	BUY	$5.17 - $16.13 $26,061 - $81,311	5,041 Added 11.07%	50,593 $756,000
Q4 2020 Feb 10, 2021	BUY	$4.01 - $7.58 $15,438 - $29,183	3,850 Added 9.23%	45,552 $246,000
Q3 2020 Nov 12, 2020	SELL	$3.8 - $5.0 $33,478 - $44,050	-8,810 Reduced 17.44%	41,702 $190,000
Q2 2020 Aug 13, 2020	BUY	$2.62 - $5.2 $45,553 - $90,412	17,387 Added 52.49%	50,512 $249,000
Q1 2020 May 06, 2020	BUY	$2.38 - $5.81 $2,132 - $5,205	896 Added 2.78%	33,125 $104,000
Q4 2019 Feb 05, 2020	BUY	$2.31 - $3.14 $1,905 - $2,590	825 Added 2.63%	32,229 $83,000
Q3 2019 Oct 23, 2019	SELL	$2.22 - $3.9 $943 - $1,657	-425 Reduced 1.34%	31,404 $99,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $87,529 - $117,767	31,829 New	31,829 $107,000
Q2 2018 Aug 06, 2018	SELL	$2.08 - $4.26 $69,777 - $142,910	-33,547 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$3.12 - $4.94 $23,056 - $36,506	-7,390 Reduced 18.05%	33,547 $108,000
Q3 2017 Nov 06, 2017	BUY	$3.42 - $4.87 $140,004 - $199,363	40,937	40,937 $169,000

Others Institutions Holding AVXL

# of Institutions

164

Shares Held

27.5M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $723M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Anavex Life Sciences Corp. Transaction History